Trial Title:
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT ID:
NCT05852691
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Paclitaxel
Pembrolizumab
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Double (Participant, Investigator)
Intervention:
Intervention type:
Drug
Intervention name:
Tobemstomig
Description:
Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease
progression or until up to 24 months after the first treatment, whichever is sooner.
Arm group label:
Arm A
Other name:
RO7247669
Intervention type:
Drug
Intervention name:
Pembrolizumab
Description:
Participants will receive IV pembrolizumab Q3W until disease progression or until up to
24 months after the first treatment, whichever is sooner.
Arm group label:
Arm B
Intervention type:
Drug
Intervention name:
Nab-Paclitaxel
Description:
Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off,
until disease progression or until up to 24 months after the first treatment, whichever
is sooner.
Arm group label:
Arm A
Arm group label:
Arm B
Summary:
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy
candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously
untreated, locally advanced, unresectable or metastatic (Stage IV) programmed
death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Metastatic or locally advanced unresectable, histologically documented
triple-negative breast cancer (TNBC) (absence of HER2-over-expression, ER, and PgR
expression by local assessment)
- HER2-low-status
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- If metastatic disease (Stage IV), measurable disease outside of the bone
- No prior systemic therapy for metastatic or locally advanced unresectable TNBC
- Tumor PD-L1 expression as documented through central testing of a representative
tumor tissue specimen
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate hematologic and end-organ function
- Negative HIV test at screening, with the following exception: individuals with a
positive HIV test at screening are eligible provided they are stable on
anti-retroviral therapy, have a CD4 count ≥ 200/uL, and have an undetectable viral
load
- Negative hepatitis B surface antigen (HBsAg) test at screening
- Positive hepatitis B surface antibody (HBsAb) test at screening, or a negative HBsAb
at screening accompanied by either of the following: negative hepatitis B core
antibody (HBcAb); positive HBcAb test followed by quantitative hepatitis B virus
(HBV) DNA < 500 IU/mL
- Negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV
antibody test followed by a negative HCV RNA test at screening
- Adequate cardiovascular function
Exclusion Criteria:
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study or
within 4 months after the final dose of tobemstomig or pembrolizumab, and 6 months
after the final dose of nab-paclitaxel
- Poor venous access
- History of malignancy within 5 years prior to consent, except for the cancer under
investigation in this study and malignancies with a negligible risk of metastasis or
death (e.g., 5-year OS rate >90%), such as adequately treated carcinoma in situ of
the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma
in situ, or Stage I uterine cancer
- Symptomatic, untreated, or actively progressing central nervous system (CNS)
metastases
- History of leptomeningeal disease
- Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage
procedures (once monthly or more frequently)
- Hypercalcemia or hypercalcemia that is symptomatic
- Active or history of autoimmune disease or immune deficiency, including, but not
limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus
erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid
antibody syndrome, Wegener granulomatosis (granulomatosis with polyangiitis),
Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
active pneumonitis on screening chest computed tomography (CT) scan. History of
radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active tuberculosis (TB)
- Significant cardiovascular/cerebrovascular disease within 3 months prior to consent
- History or presence of an abnormal ECG that is deemed clinically significant
- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
such as structural heart disease (e.g., severe left ventricular systolic
dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or
with ischemia demonstrated by diagnostic testing), clinically significant
electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or
family history of sudden unexplained death or long QT syndrome
- Major surgical procedure within 4 weeks prior to initiation of study treatment
- Treatment with therapeutic oral or IV antimicrobials (anti-bacterial, anti-fungal,
antiviral, anti-parasitic) within 1 week prior to initiation of study treatment
- Prior allogeneic stem cell or solid organ transplantation
- Any other disease, metabolic dysfunction, physical examination finding, or clinical
laboratory finding that contraindicates the use of an investigational drug, may
affect the interpretation of the results, or may render the participant at high risk
from treatment complications
- Treatment with a live, attenuated vaccine within 28 days prior to initiation of
study treatment
- Treatment with investigational therapy within 28 days prior to initiation of study
treatment
- Prior treatment with CD137 agonists or anti-CTLA therapeutic antibodies or an
anti-LAG3 agent
- Treatment with systemic immunostimulatory agents (including, but not limited to,
interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is
longer) prior to initiation of study treatment
- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications (including, but not limited to, prednisone, dexamethasone,
cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents)
within 2 weeks prior to initiation of study treatment
- History of severe allergic anaphylactic reactions to chimeric or humanized
antibodies or fusion proteins
- Known hypersensitivity to Chinese hamster ovary cell products or to any component of
the tobemstomig or pembrolizumab formulation
- Known allergy or hypersensitivity to any component of the to nab-paclitaxel
formulation
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Cancer Blood and Specialty Clinic
Address:
City:
Los Alamitos
Zip:
90720
Country:
United States
Status:
Recruiting
Facility:
Name:
Lawrence J. Ellison Institute for Transformative Medicine
Address:
City:
Los Angeles
Zip:
90064
Country:
United States
Status:
Recruiting
Facility:
Name:
UCSF Comprehensive Cancer Ctr
Address:
City:
San Francisco
Zip:
94158
Country:
United States
Status:
Recruiting
Facility:
Name:
Providence St Johns Health Center
Address:
City:
Santa Monica
Zip:
90404
Country:
United States
Status:
Recruiting
Facility:
Name:
Cedars Sinai Outpatient Cancer Center
Address:
City:
West Hollywood
Zip:
90048
Country:
United States
Status:
Recruiting
Facility:
Name:
University of Colorado Hospital - Anschutz Cancer Pavilion
Address:
City:
Aurora
Zip:
80045
Country:
United States
Status:
Recruiting
Facility:
Name:
University of Colorado Health Lone Tree Medical Center
Address:
City:
Lone Tree
Zip:
80124
Country:
United States
Status:
Recruiting
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Facility:
Name:
Mercy Medical Center
Address:
City:
Baltimore
Zip:
21202
Country:
United States
Status:
Recruiting
Facility:
Name:
Frederick Health Hospital
Address:
City:
Frederick
Zip:
21701
Country:
United States
Status:
Recruiting
Facility:
Name:
Washington University; Wash Uni. Sch. Of Med
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Facility:
Name:
Memorial Sloan-Kettering Cancer Center
Address:
City:
New York
Zip:
10065
Country:
United States
Status:
Recruiting
Facility:
Name:
Novant Health Presbyterain Medical Center
Address:
City:
Charlotte
Zip:
28204
Country:
United States
Status:
Recruiting
Facility:
Name:
Novant Health Forsyth Medical Center
Address:
City:
Winston-Salem
Zip:
27103
Country:
United States
Status:
Recruiting
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Facility:
Name:
Providence Oncology and Hematology Care Clinic - Westside
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Facility:
Name:
Avera Cancer Institute
Address:
City:
Sioux Falls
Zip:
57105
Country:
United States
Status:
Recruiting
Facility:
Name:
Bon Secours Mercy Health
Address:
City:
Midlothian
Zip:
23114
Country:
United States
Status:
Recruiting
Facility:
Name:
Kadlec Clinic Hematology and Oncology
Address:
City:
Kennewick
Zip:
99336-7774
Country:
United States
Status:
Recruiting
Facility:
Name:
Swedish Cancer Inst.
Address:
City:
Seattle
Zip:
98104
Country:
United States
Status:
Recruiting
Facility:
Name:
Fundación CENIT para la Investigación en Neurociencias
Address:
City:
Buenos Aires
Zip:
C1125ABD
Country:
Argentina
Status:
Recruiting
Facility:
Name:
Cemic; Oncologia Clinica
Address:
City:
Buenos Aires
Zip:
C1431FWN
Country:
Argentina
Status:
Recruiting
Facility:
Name:
Centro Oncologico Korben
Address:
City:
Caba
Zip:
C1426AGE
Country:
Argentina
Status:
Recruiting
Facility:
Name:
Centro Oncologico Riojano Integral (CORI)
Address:
City:
La Rioja
Zip:
F5300COE
Country:
Argentina
Status:
Recruiting
Facility:
Name:
Sanatorio Parque de Rosario
Address:
City:
Rosario
Zip:
S2000KZD
Country:
Argentina
Status:
Recruiting
Facility:
Name:
Hospital Provincial del Centenario
Address:
City:
Rosario
Zip:
S2002KDS
Country:
Argentina
Status:
Recruiting
Facility:
Name:
ICON Cancer Care Adelaide
Address:
City:
Kurralta Park
Zip:
5037
Country:
Australia
Status:
Recruiting
Facility:
Name:
Sunshine Hospital; Oncology Research
Address:
City:
St Albans
Country:
Australia
Status:
Active, not recruiting
Facility:
Name:
Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit
Address:
City:
Bull Creek
Zip:
6149
Country:
Australia
Status:
Recruiting
Facility:
Name:
Hospital Sao Rafael - HSR
Address:
City:
Salvador
Zip:
41253-190
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital Araujo Jorge; Departamento de Ginecologia E Mama
Address:
City:
Goiania
Zip:
74605-070
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital do Cancer de Pernambuco - HCP
Address:
City:
Recife
Zip:
50040-000
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital de Amor Amazônia
Address:
City:
Porto Velho
Zip:
76834-899
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital Nossa Senhora da Conceicao
Address:
City:
Porto Alegre
Zip:
90040-373
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital Sao Lucas - PUCRS
Address:
City:
Porto Alegre
Zip:
90610-000
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Hospital de Cancer de Barretos
Address:
City:
Barretos
Zip:
14784-400
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
Address:
City:
Sao Paulo
Zip:
01317-001
Country:
Brazil
Status:
Recruiting
Facility:
Name:
Nemocnice AGEL Novy Jicin a.s.; Oddeleni radioterapie a onkologie
Address:
City:
Novy Jicin
Zip:
741 01
Country:
Czechia
Status:
Recruiting
Facility:
Name:
Fakultni nemocnice Olomouc; Onkologicka klinika
Address:
City:
Olomouc
Zip:
779 00
Country:
Czechia
Status:
Recruiting
Facility:
Name:
Fakultni Thomayerova nemocnice; Onkologicka klinika 1. LF UK a FTN
Address:
City:
Praha 4 - Krc
Zip:
140 59
Country:
Czechia
Status:
Recruiting
Facility:
Name:
Fakultni nemocnice v Motole; Onkologicka klinika 2. LF UK a FN Motol
Address:
City:
Praha 5
Zip:
150 06
Country:
Czechia
Status:
Recruiting
Facility:
Name:
Centre Hospitalier Universitaire de Treichville; Oncologie Médicale - Chirurgie
Address:
City:
Abidjan
Zip:
01BPV03
Country:
Côte D'Ivoire
Status:
Recruiting
Facility:
Name:
Aalborg Universitetshospital; Onkologisk Afdeling
Address:
City:
Aalborg
Zip:
9000
Country:
Denmark
Status:
Recruiting
Facility:
Name:
Rigshospitalet; Onkologisk Klinik
Address:
City:
København Ø
Zip:
2100
Country:
Denmark
Status:
Recruiting
Facility:
Name:
Odense Universitetshospital, Onkologisk Afdeling R
Address:
City:
Odense C
Zip:
5000
Country:
Denmark
Status:
Recruiting
Facility:
Name:
Vejle Sygehus; Onkologisk Afdeling
Address:
City:
Vejle
Zip:
7100
Country:
Denmark
Status:
Recruiting
Facility:
Name:
Klinikum Augsburg; Frauenklinik
Address:
City:
Augsburg
Zip:
86156
Country:
Germany
Status:
Recruiting
Facility:
Name:
Das Brustzentrum
Address:
City:
Berlin
Zip:
12623
Country:
Germany
Status:
Recruiting
Facility:
Name:
St. Johannes Hospital; Abt. für Hämatologie und Onkologie
Address:
City:
Dortmund
Zip:
44137
Country:
Germany
Status:
Recruiting
Facility:
Name:
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum
Address:
City:
Essen
Zip:
45136
Country:
Germany
Status:
Recruiting
Facility:
Name:
Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe
Address:
City:
Esslingen
Zip:
73730
Country:
Germany
Status:
Recruiting
Facility:
Name:
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Address:
City:
Freiburg
Zip:
79110
Country:
Germany
Status:
Recruiting
Facility:
Name:
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
Address:
City:
Hannover
Zip:
30625
Country:
Germany
Status:
Withdrawn
Facility:
Name:
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
Address:
City:
Heidelberg
Zip:
69120
Country:
Germany
Status:
Recruiting
Facility:
Name:
InVO - Institut für Versorgungsforschung in der Onkologie GbR
Address:
City:
Koblenz
Zip:
56068
Country:
Germany
Status:
Recruiting
Facility:
Name:
Dres. Andreas Köhler und Roswitha Fuchs
Address:
City:
Langen
Zip:
63225
Country:
Germany
Status:
Recruiting
Facility:
Name:
Onkologische Schwerpunktpraxis Lübeck
Address:
City:
Lübeck
Zip:
23562
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
Address:
City:
Mainz
Zip:
55131
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe
Address:
City:
Münster
Zip:
48149
Country:
Germany
Status:
Recruiting
Facility:
Name:
Gemeinschaftspraxis für Hämatologie und Onkologie
Address:
City:
Münster
Zip:
48153
Country:
Germany
Status:
Recruiting
Facility:
Name:
HELIOS Klinikum Schwerin; Frauenklinik
Address:
City:
Schwerin
Zip:
19049
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Ulm Am Michelsberg; Frauenklinik
Address:
City:
Ulm
Zip:
89075
Country:
Germany
Status:
Recruiting
Facility:
Name:
Somogy Varmegyei Kaposi Mor Oktato Korhaz; Onkologiai Osztaly
Address:
City:
Kaposvár
Zip:
7400
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Bács-Kiskun Vármegyei Oktatókórház; Onkoradiológiai Központ
Address:
City:
Kecskemét
Zip:
6000
Country:
Hungary
Status:
Recruiting
Facility:
Name:
B-A-Z Vármegyei Központi Kórház és Egyetemi Oktatókórház; Klin. Onkológiai és Sugárterápiás Centrum
Address:
City:
Miskolc
Zip:
3526
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Komarom-Eszergom Varmegyei Szent Borbala Korhaz; Onkologiai Osztaly
Address:
City:
Tatabanya
Zip:
2800
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Hadassah University Hospital - Ein Kerem; Oncology
Address:
City:
Jerusalem
Zip:
9112001
Country:
Israel
Status:
Active, not recruiting
Facility:
Name:
Sheba Medical Center
Address:
City:
Ramat Gan
Zip:
5262100
Country:
Israel
Status:
Active, not recruiting
Facility:
Name:
Sourasky / Ichilov Hospital; Dept. of Oncology
Address:
City:
Tel Aviv
Zip:
6423906
Country:
Israel
Status:
Recruiting
Facility:
Name:
Policlinico S.Orsola-Malpighi; Istituto Oncologia R. Addarii
Address:
City:
Bologna
Zip:
40138
Country:
Italy
Status:
Recruiting
Facility:
Name:
Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica
Address:
City:
Ravenna
Zip:
48100
Country:
Italy
Status:
Active, not recruiting
Facility:
Name:
RCCS - Centro di Riferimento; Oncologia Medica B
Address:
City:
Aviano (PN)
Zip:
33081
Country:
Italy
Status:
Recruiting
Facility:
Name:
Ospedale San Raffaele; Medical Oncology
Address:
City:
Milano
Zip:
20132
Country:
Italy
Status:
Recruiting
Facility:
Name:
Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica
Address:
City:
Milano
Zip:
20141
Country:
Italy
Status:
Recruiting
Facility:
Name:
Ospedale S. Giuseppe; Oncologia
Address:
City:
Empoli (FI)
Zip:
50053
Country:
Italy
Status:
Recruiting
Facility:
Name:
Ospedale Civile; Unita Operativa Di Oncologia Medica
Address:
City:
Livorno
Zip:
57100
Country:
Italy
Status:
Recruiting
Facility:
Name:
Seoul National University Hospital
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Status:
Recruiting
Facility:
Name:
Asan Medical Center
Address:
City:
Seoul
Zip:
05505
Country:
Korea, Republic of
Status:
Recruiting
Facility:
Name:
Gangnam Severance Hospital, Yonsei University Health System
Address:
City:
Seoul
Zip:
06273
Country:
Korea, Republic of
Status:
Active, not recruiting
Facility:
Name:
Samsung Medical Center
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Status:
Active, not recruiting
Facility:
Name:
Health Pharma Professional Research
Address:
City:
Cdmx
Zip:
03100
Country:
Mexico
Status:
Recruiting
Facility:
Name:
OncoMed; Supportive Care
Address:
City:
Ciudad de México
Zip:
03100
Country:
Mexico
Status:
Active, not recruiting
Facility:
Name:
Centro Médico Zambrano Hellion
Address:
City:
Monterrey
Zip:
66278
Country:
Mexico
Status:
Active, not recruiting
Facility:
Name:
Centro de Investigacion Clinica de Oaxaca
Address:
City:
Oaxaca de Juárez
Zip:
68020
Country:
Mexico
Status:
Recruiting
Facility:
Name:
Ziekenhuis Gelderse Vallei
Address:
City:
EDE
Zip:
6716 RP
Country:
Netherlands
Status:
Recruiting
Facility:
Name:
Centro Medico Monte Carmelo
Address:
City:
Arequipa
Zip:
04001
Country:
Peru
Status:
Recruiting
Facility:
Name:
Instituto Nacional de Enfermedades Neoplasicas
Address:
City:
Lima
Zip:
15038
Country:
Peru
Status:
Recruiting
Facility:
Name:
Instituto Peruano de Oncología y Radioterapia
Address:
City:
Lima
Zip:
15072
Country:
Peru
Status:
Recruiting
Facility:
Name:
Oncosalud Sac; Oncología
Address:
City:
Lima
Zip:
41
Country:
Peru
Status:
Recruiting
Facility:
Name:
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka; Ambulatorium Chemioterapii
Address:
City:
Bydgoszcz
Zip:
85-796
Country:
Poland
Status:
Recruiting
Facility:
Name:
Narodowy Instytut Onkologii Odzia? w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi
Address:
City:
Gliwice
Zip:
44-102
Country:
Poland
Status:
Recruiting
Facility:
Name:
?wi?tokrzyskie Centrum Onkologii; Dzia? Chemioterapii
Address:
City:
Kielce
Zip:
25-734
Country:
Poland
Status:
Recruiting
Facility:
Name:
Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii
Address:
City:
Koszalin
Zip:
75-581
Country:
Poland
Status:
Recruiting
Facility:
Name:
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
Address:
City:
Kraków
Zip:
30-688
Country:
Poland
Status:
Active, not recruiting
Facility:
Name:
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr
Address:
City:
Warszawa
Zip:
02-781
Country:
Poland
Status:
Recruiting
Facility:
Name:
Medical Oncology Centre of Rosebank; Oncology
Address:
City:
Johannesburg
Zip:
2196
Country:
South Africa
Status:
Active, not recruiting
Facility:
Name:
Cancercare
Address:
City:
Port Elizabeth
Zip:
6045
Country:
South Africa
Status:
Recruiting
Facility:
Name:
Steve Biko Academic Hospital; Oncology
Address:
City:
Pretoria
Zip:
0002
Country:
South Africa
Status:
Recruiting
Facility:
Name:
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
Address:
City:
Santiago de Compostela
Zip:
15706
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Quiron de Madrid; Servicio de Oncologia
Address:
City:
Pozuelo de Alarcon
Zip:
28223
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Virgen de La Arrixaca; Servicio De Oncologia
Address:
City:
El Palmar
Zip:
30120
Country:
Spain
Status:
Active, not recruiting
Facility:
Name:
Complejo Hospitalario de Navarra; Servicio de Oncologia
Address:
City:
Pamplona
Zip:
31008
Country:
Spain
Status:
Recruiting
Facility:
Name:
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
Address:
City:
Madrid
Zip:
28050
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
Address:
City:
Malaga
Zip:
29010
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
Address:
City:
Sevilla
Zip:
41013
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Address:
City:
Valencia
Zip:
46010
Country:
Spain
Status:
Recruiting
Facility:
Name:
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
Address:
City:
Taipei City
Zip:
11259
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
VETERANS GENERAL HOSPITAL; Department of General Surgery
Address:
City:
Taipei
Zip:
00112
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
National Taiwan Uni Hospital; Dept of Oncology
Address:
City:
Taipei
Zip:
100
Country:
Taiwan
Status:
Active, not recruiting
Facility:
Name:
Chang Gung Memorial Hosipital at Linkou
Address:
City:
Taoyuan City
Zip:
333
Country:
Taiwan
Status:
Recruiting
Start date:
July 18, 2023
Completion date:
February 27, 2026
Lead sponsor:
Agency:
Hoffmann-La Roche
Agency class:
Industry
Source:
Hoffmann-La Roche
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05852691
